- Pharmaron’s preliminary net income for the first half of 2024 increased by 34% to 45%.
- The preliminary net income range is between 1.06 billion yuan and 1.14 billion yuan.
- This outperforms the analyst estimates, which averaged at 600.5 million yuan.
- Preliminary revenue figures are between 5.47 billion yuan and 5.64 billion yuan.
- These revenue figures are slightly below the analyst estimate of 5.69 billion yuan.
- Analyst recommendations for Pharmaron include 24 “buys,” 2 “holds,” and 3 “sells.”
A look at Pharmaron Beijing Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Pharmaron Beijing, a company based in China, has received encouraging Smart Scores in various key areas. With a solid Growth score of 4 and Momentum score of 4, the company is showing promising signs for its future performance. This indicates that Pharmaron Beijing is positioned for potential growth and has strong positive momentum in the market.
Furthermore, Pharmaron Beijing also demonstrates resilience with a score of 3, suggesting that the company has the ability to withstand challenges and maintain stability. Although its Value score is moderate at 2 and Dividend score at 3, the company’s focus on growth and momentum bodes well for its long-term outlook in the industry.
### Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
